Ferring Educational Programm

Hosted online by IVF-Worldwide.com

BASIC UNDERSTANDING OF THE LUTEAL SUPPORT (LPS) IN ART TREATMENT CYCLES (Summary of the program)

Capsule: Ovarian stimulation results in supraphysiological steroid concentrations along with low LH levels during the luteal phase, approximately 8-9 days after hCG administration. This results in decreased corpus luteum production of estrogen and progesterone, which is associated with decreased probability of successful implantation and ongoing pregnancy.The triggering of the final stages of ovulation using either hCG (5,000-10,00IU) or GnRH-a induce specific, yet different adverse consequences on the luteal phase that call for corrective measures. The program developed below was built to raise the controversies on the subject, striving to reach a consensus regarding lutal support in ART cycles.


Session 1

Chairpersons: Dominique De Ziegler, France; Zeev Shoham, Israel

Is there a dose-effect relationship in the endometrial effects of progesterone ?
Dominique De Ziegler, France
Why do we need additional progesterone when endogenous levels are so high?
Pedro Barri, Spain

Panel discussion

Should LPS be adjusted to the COS regime?
Milton Leong, Hong Kong
Luteal phase support in ovulation induction cycles
Salim Daya, Canada
Which formulation should we use?
Roy Homburg, Israel
Which is the optimal duration of LPS in pregnancy: Science vs. clinical practice
Zeev Shoham, Israel
Is there a place for IM progesterone supplementation ?
Sherman Silber, USA

Session 2

How do we choose the treatment?
Chairpersons: Dominique De Ziegler, France; Zeev Shoham, Israel; Sedat Kadanalı, Turkey

Luteal support in ART treatment cycles: Is there a place for new/old formulation?
Salim Daya, Canada
Latest results from IVF worldwide survey
Zeev Shoham, Israel
Luteal phase after GnRH agonist ovulation triggering
Seang Lin Tan, Canada

Panel discussion

Is there a risk involved in additional or high dose progesterone during the luteal phase or early pregnancy?
Dominique De Ziegler, France
Is there a role for gonadotropin releasing hormone (GnRH)-agonists as a luteal supplement in GnRH- agonist and antagonist stimulated cycles?
Pedro Barri, Spain
Active management of the luteal phase
Baris Ata, Turkey
Should hCG be added to all supplemented protocols?
Gedis Grudzinskas, UK
Is there a need for additional estrogen supplementation?
Ariel Weissman, Israel

View Symposium Summary